AI Tool Detects Occult Pancreatic Cancer Months in Advance

Published Date: 11 Jun 2026

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.

Read Full News

Latest News

Novo Nordisk Flags Patient Data Breach From Some Clinical Trials in Cyberattack

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide Outperforms Conventional Care in Early Diabetes

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

AI-Guided Prep Improves Bariatric Surgery Consults

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

PMOS: Insulin Resistance Affects Fertility and Pregnancy

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

Over-the-Counter CGM Okayed for Kids

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

Novel Oral GLP-1 Shows A1c and Weight-Loss Benefits

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Latest News

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

News All Time

Beyond BMI: New Score Stratifies Obesity Risk

BMI, while useful, is insufficient to identify patients at the highest risk for obesity-related complications. A new tool may help clinicians better stratify risk and target treatment.

Tango Therapeutics' Pancreatic Cancer Drug Combo Shows Promise in Study

Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients ⁠with advanced pancreatic cancer and that it...

Liver-Directed Insulin: A New Way to Reduce Hypoglycemia?

Study findings suggest that a liver-targeted formulation of fast-acting insulin may reduce the risk for hypoglycemia in patients with type 1 diabetes.

Moving Beyond GLP-1s: Preclinical Acceleration, Innovation

Next-generation obesity therapeutics aim to counter weight rebound, decrease side effects, and support weight maintenance.

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.

Do Corticosteroids Really Raise Gestational Diabetes Risk?

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

From Taboo to Test: Can Menstrual Blood Aid Diagnosis?

Emerging research suggests that menstrual blood may provide valuable diagnostic and biological insights, with potential applications in cancer screening and endometriosis detection.

No Increased Retinopathy Risk Seen With Tirzepatide

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

Petrelintide Tolerability Could Improve on GLP-1 Challenges

The amylin analog petrelintide reduces body weight with 'placebo-like' tolerability, a phase 2 trial shows.

CGM Monitoring Benefits Extend to Non-Insulin-Using T2D

Patients with type 2 diabetes not taking insulin who use continuous glucose monitoring show significant reductions in A1c.

Obesity Meds Improve Patients' Perceived Physical Function

Obesity management medications improve patients' perceived physical function and have a 'modest' impact on an objective functional measure.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Glucose Excursions Drive CGM-A1c Discordance in Monitoring

Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, according to a new study.

Danish Study Links Type 1 Diabetes to Femoral Fractures

Both T1D and T2D are linked to a higher incidence of subtrochanteric or femoral shaft and hip fractures, but after adjusting for age, only the association for T1D remains significant.

Primary Infertility Linked to Earlier Menopause Onset

Women with primary infertility undergo natural menopause earlier than women without infertility.

Exclusive-Cigna Drops Coverage Of GLP-1 Obesity Drugs for Its Own Employees

Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee ⁠health plan effective July 1,...

Recommended News For You

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Getting More Done With Less Blood.

A study on lung cancer provides additional proof of the value of screening.

Trump slashed US cancer research by 31 percent: Senate report

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

O. A. J. Simpson passes away from cancer.

Recommended Articles For You

Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength 

Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients 

From Bruises to Blood Clots: Everything You Need to Know about Hematoma  

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

2.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

3.

Millions of men could benefit from faster scan to diagnose prostate cancer

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy

1.

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends

2.

A Closer Look at the Effects of Sickle Cell on Eyesight

3.

Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection

4.

Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care

5.

Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

4.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

5.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot